Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

This study has been completed.
Information provided by (Responsible Party):
Sorrento Therapeutics, Inc. Identifier:
First received: February 14, 2014
Last updated: March 23, 2016
Last verified: March 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2015
  Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)